Last updated: July 28, 2026
What is the current clinical trial status of nateglinide?
Nateglinide is an older, commercially established insulin secretagogue (benzaldehyde-derived D-phenylalanine derivative class) used in type 2 diabetes for glycemic control. Public clinical-trials activity is limited relative to newer antidiabetic classes, with most recent visible activity focused on comparative physiology, combination regimens, and adherence or dosing refinement rather than pivotal FDA-defining programs.
What typically appears in recent nateglinide registries (high level)
- Small, investigator-led or sponsor-led studies evaluating postprandial glucose control.
- Combination studies with metformin or other oral agents.
- Pharmacokinetic or meal-tolerance type studies.
- Quality-of-life or adherence endpoints paired with glycemic outcomes.
Where the major “update” pressure is coming from
- Regulatory and commercial focus has shifted to incretin-based and SGLT2 inhibitor portfolios in many markets.
- Nateglinide remains a targeted postprandial therapy option in some geographies and formulary designs, which tends to reduce incentives for large, late-stage trials.
Are there any active phase 3 or registrational trials for nateglinide?
No registrational phase 3 trials that clearly indicate a contemporary FDA- or EMA-defining pathway were evident in public sources at the time of this build. Clinical-trials visibility for nateglinide is dominated by non-pivotal work, which is consistent with its established role and older approval basis.
Which trial endpoints matter for nateglinide studies now?
- Postprandial glucose (PPG) AUC or excursions after standardized meals
- 2-hour PPG or pre/post meal glucose comparisons
- HbA1c change in short-to-medium duration combination or switching studies
- Safety endpoints centered on hypoglycemia incidence and severity
- Tolerability and treatment persistence
How does nateglinide compare with other mealtime insulin secretagogues like repaglinide?
Nateglinide and repaglinide are both short-acting secretagogues used around meals, but their clinical use patterns differ by geography, formulary access, and clinician preference. Comparative literature commonly frames nateglinide as a postprandial-focused option with dosing tied to meals.
Competitive positioning snapshot
- Secretagogue class competes with: DPP-4 inhibitors, GLP-1 receptor agonists, and prandial insulin strategies depending on line of therapy.
- Within secretagogues: repaglinide frequently has broader adoption and market pull in some regions, affecting pricing and persistence of nateglinide.
What is the current market size and sales trajectory for nateglinide?
Nateglinide is a niche oral antidiabetic globally relative to blockbuster diabetes drugs. Market performance tends to track:
- Patent and generic availability in key countries
- Formulary inclusion in national healthcare systems
- Presence in fixed-dose combinations or combo formularies
- Uptake as a postprandial-targeted option
Market trajectory drivers
- Generic penetration: As with most older oral diabetes drugs, generic share compresses unit economics.
- Shifting standard of care: Incretins and SGLT2 inhibitors have displaced many secretagogues for first-line or early intensification in multiple markets.
- Formulary pressure: Health systems increasingly prefer once-daily or weekly regimens or agents with cardiovascular or renal outcomes.
What is the likely revenue projection for nateglinide through 2030?
A credible projection requires country-level demand data and current price/volume by dosage strength and brand vs generic share. Those inputs are not present in the materials used for this response, so a defensible numeric forecast cannot be produced here without introducing unsupported numbers.
Which companies control nateglinide supply today and how does that affect pricing?
For older oral drugs, the market is typically split between:
- Original brand history owner (where applicable by jurisdiction)
- Multiple generic entrants holding ANDA/marketing authorizations
- Local distributors and pharmacy chain private labels in select markets
Pricing and access effects
- High generic substitution compresses net price and limits revenue growth.
- Competition often concentrates at the store pharmacy and reimbursement level rather than at the prescriber level, affecting tender outcomes and formulary retention.
What is the patent and exclusivity landscape for nateglinide (and what does it mean for new market entry)?
Nateglinide is an established drug. In most jurisdictions, active exclusivity related to the original product has largely run out, leaving generics and line-extension products (if any) as the practical IP boundary.
What would block a generic or biosimilar competitor for nateglinide?
For small-molecule drugs like nateglinide, the major barriers are:
- Unexpired formulation, polymorph, salt, or manufacturing-process patents
- Method-of-use patents (less common in practice for older oral antidiabetics)
- Any current marketing authorizations tied to specific dosage forms
When does nateglinide lose exclusivity in key markets like the US and EU?
A market-ready exclusivity timeline requires mapping Orange Book listings (US) and national EP/RP patent filings plus SPC records (EU). Those specific listings are not provided here, so an accurate “lose exclusivity” date cannot be stated.
What is the Orange Book status of nateglinide?
This requires retrieving the specific Orange Book entry for nateglinide products (including NDA/ANDA codes, listed patents, and expiration dates). Those data are not available in the materials used for this response, so a correct Orange Book status cannot be produced.
What patent litigation affects nateglinide generic entry?
A litigation summary requires case-level details (e.g., Paragraph IV filings, district court dockets, settlement agreements, or appeal outcomes). No case record set was provided, so a reliable litigation status cannot be stated.
What generic entry risks exist for nateglinide?
For an older small molecule with broad generic availability in many countries, new “entry risk” usually comes from:
- Formulation-specific protections still in-force
- Process or polymorph controls that apply only to particular products or manufacturing lines
- Local regulatory constraints or market withdrawals
A product-specific risk assessment needs current regulatory and patent status by jurisdiction, which is not included in the inputs used here.
Which formulations are most relevant commercially for nateglinide?
Clinical and commercial use is centered on immediate-release oral dosing timed around meals. Market relevance typically tracks:
- Tablet strength availability
- Bioequivalence acceptance across generic products
- Formulary dosing instructions by reimbursement policy
Without current label and product-form inventory by country, a complete formulation map cannot be produced.
How does nateglinide’s safety profile affect adoption and market share?
Class safety signals that influence prescribing include:
- Hypoglycemia risk, especially when combined with other glucose-lowering agents
- Gastrointestinal tolerability and adherence tied to meal timing
Adoption tends to weaken when clinicians shift toward agents with lower meal-timing complexity, or agents with proven cardiometabolic outcome benefits.
Key competitive landscape questions for nateglinide
Does nateglinide compete mainly with DPP-4 inhibitors, GLP-1s, or SGLT2 inhibitors?
In many formularies, it competes more as a targeted add-on for postprandial control than as a primary intensification agent. Actual competitive overlap depends on:
- Step therapy rules
- HbA1c thresholds for agent selection
- Hypoglycemia risk mitigation preferences
- Coverage for injectables vs oral secretagogues
How does nateglinide compare with repaglinide and other secretagogues?
Competitive differentiation is usually framed around:
- Postprandial glucose reduction magnitude
- Dosing convenience and meal timing adherence requirements
- Hypoglycemia frequency in specific patient subgroups
Commercial projection framework used for nateglinide
A robust projection for an older generic-dominated oral antidiabetic should be built from:
- Current generic and brand mix by country
- Net price erosion trends
- Volume growth tied to diabetes prevalence and adherence
- Formulary tenure and tender cycles
- Drug switching patterns driven by new outcomes-based therapies
This response cannot compute those numeric drivers without source data.
Key Takeaways
- Nateglinide’s visible clinical activity is primarily non-pivotal or comparative, consistent with its established role in type 2 diabetes.
- Competitive pressure comes from broader diabetes drug classes and shifting guideline adoption toward agents with cardiometabolic outcome data.
- Market performance is constrained by generic penetration and tends to be steady-to-declining rather than expanding, unless a specific geography and formulary environment sustains demand.
- A defensible exclusivity timeline, Orange Book status, and litigation assessment require product-specific patent and regulatory listings, which are not included in the available inputs for this response.
FAQs
- What is nateglinide’s main clinical use and dosing purpose in type 2 diabetes?
- Is nateglinide still being studied in new clinical trials, or is activity mostly comparative/PK work?
- How does nateglinide’s hypoglycemia risk compare with other oral diabetes drugs in combination therapy?
- What factors most affect nateglinide’s market share in generic-dominated environments?
- How do meal-timed secretagogues like nateglinide fit into modern diabetes treatment algorithms versus GLP-1 and SGLT2 therapies?
References
- [No sources were provided in the prompt; no external citations can be accurately produced.]
